Clinical trials in Europe need to be much more efficient to support the needs of investigators and patients. The way studies are designed, conducted and regulated should be adapted to the needs of patients for timely and equitable access to safe, effective and innovative treatments. Excessive bureaucracy increases complexity, costs, and limits investigators' time to care for patients. A coalition of medical societies and patient representatives is calling for urgent measures to reduce the administrative burden. It recommends simplifying safety reporting, making informed consent more understandable and harmonizing requirements in the EU. These changes are intended to preserve patient safety and study quality while leveraging lessons learned from the COVID-19 pandemic. The goal is to make clinical trials more efficient, cheaper, and patient-centered.[1][2][3][4][5]